Stockreport

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 [Yahoo! Finance]

Thryv Holdings, Inc.  (THRY) 
PDF Wave II is informed by the successful Wave I clinical study with LQT-1213 and reinforced by significant QTcF reductions observed in a subsequent clinical study with THR [Read more]